Solid Biosciences Inc. reported on November 3, 2025, positive interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial for SGT-003, a treatment for Duchenne muscular dystrophy. Key findings included a mean microdystrophin expression of 58% and notable reductions in serum creatine kinase levels, suggesting effective muscle preservation.